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Abstract
Background: Invasive cervical cancer is the second most common malignant tumor affecting Brazilian women.
Knowledge on Human Papillomavirus (HPV) genotypes in invasive cervical cancer cases is crucial to guide the
introduction and further evaluate the impact of new preventive strategies based on HPV. We aimed to provide
updated comprehensive data about the HPV types’ distribution in patients with invasive cervical cancer.
Methods: Fresh tumor tissue samples of histologically confirmed invasive cervical cancer were collected from 175
women attending two cancer reference hospitals from São Paulo State: ICESP and Hospital de Câncer de Barretos.
HPV detection and genotyping were performed by the Linear Array HPV Genotyping Test (Roche Molecular
Diagnostics, Pleasanton,USA).
Results: 170 out of 172 valid samples (99%) were HPV DNA positive. The most frequent types were HPV16 (77.6%),
HPV18 (12.3%), HPV31 (8.8%), HPV33 (7.1%) and HPV35 (5.9%). Most infections (75%) were caused by individual HPV
types. Women with adenocarcinoma were not younger than those with squamous cell carcinoma, as well, as
women infected with HPV33 were older than those infected by other HPV types. Some differences between results
obtained in the two hospitals were observed: higher overall prevalence of HPV16, absence of single infection by
HPV31 and HPV45 was verified in HC-Barretos in comparison to ICESP patients.
Conclusions: To our knowledge, this is one of the largest studies made with fresh tumor tissues of invasive cervical
cancer cases in Brazil. This study depicted a distinct HPV genotype distribution between two centers that may
reflect the local epidemiology of HPV transmission among these populations. Due to the impact of these findings
on cervical cancer preventive strategies, extension of this investigation to routine screening populations
is warranted.
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Background
Invasive cervical cancer (ICC) is the third most common
neoplasia among women worldwide, representing 8.8% of
all cancers. Worldwide 607,402 new cases of ICC are pre-
dicted to occur by 2015 [1], 493,668 affecting women aged
less than 65 years with 320,832 attributable deaths. In
Brazil, ICC is the second most common cancer among
women and the National Cancer Institute (INCA), agency
of the Ministry of Health responsible for cancer preven-
tion and control policies, estimated that 17,540 new cases
of ICC would occur in 2012, 2,880 of these affecting the
São Paulo State [2]. Brazil’s efforts for ICC prevention are
based on a national programme of cervical cancer screen-
ing that recommends periodic cervical cytology to women
aged 25 to 64 years [2].
Anogenital infection by HPV is associated with benign
lesions, like condylomata acuminata, and malignant le-
sions, especially in the uterine cervix [3]. More than 120
HPV types were described based on the isolation of
complete genomes [4,5], 40 of these are known to infect
the anogenital tract [6] and 12 are classified as carcinogens
[7]. Virtually all ICC cases are thought to be preceded by a
persistent high-risk HPV genital infection [8,9]. HPV16
and 18 together are responsible for 70% of all ICC cases
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globally and are the two most frequent HPV types in all
geographical regions, while the third most common HPV
type varies according to country and population group
[10-12]. Several studies investigated HPV genotypes con-
tribution among ICC cases of the Brazilian population. All
them reported HPV16 and 18 as the most frequent HPV
types [13-16], followed by HPV 31 and 33 [13,14], with ex-
ception of the Northeast region, where the third most
common HPV type is HPV58, followed by HPV45 [16].
Two prophylactic vaccines against high-risk HPV16
and 18 were licensed, a bivalent (HPV16 and 18) and a
quadrivalent one (HPV6, 11, 16 and 18). In Brazil, these
two HPV vaccines are available only in private clinics
and due to their high cost are not accessible to most of
the population. Its inclusion in the national programme
of immunization remains under debate [2]. The present
study provides an update on HPV genotypes distribution
in samples of ICC from patients attending two major
reference cancer hospitals in São Paulo State, attempting
to identify multiple infections and investigate the associ-
ation between specific histological types and HPV geno-
types. Knowledge of HPV genotypes associated to ICC
may contribute to the assessment of the impact of
current HPV vaccines on the future incidence of these
lesions and assist in the decision making of future pre-
vention strategies.
Methods
Study population
Between November 2009 and July 2011 women with a
diagnosis of invasive cervical cancer were recruited from
two reference cancer hospitals in São Paulo State: Instituto
do Câncer do Estado de São Paulo (ICESP) and Hospital
de Câncer de Barretos – Fundação Pio XII (HC-Barretos).
ICESP is a tertiary public hospital located in São Paulo
city, the largest city in South America, with approximately
11 million inhabitants [17]. HC-Barretos is a non-profit
hospital sustained by a charity foundation, in the city of
Barretos, approximately 450 km distant from São Paulo
city, both in the same state. São Paulo city is a well ad-
vanced medical center attracting thousands of patients
from all over Latin America. It is a cosmopolitan center,
home to immigrants from all over the world. In contrast,
Barretos is a small city of 115 thousand inhabitants [17]
but the HC-Barretos also attracts patients from the whole
country, promoting cancer prevention in a vast number of
inland cities in the surroundings of Barretos and also in
distant remote areas.
At the moment of study enrollment and sample collec-
tion all patients were naïve to cancer treatment. One
hundred and ninety four patients were initially included
in the study and had two biopsies collected: one for the
histopathological diagnosis and another for the study.
Nineteen patients were further excluded due to absence
of confirmation of invasive cervical cancer by histopath-
ology. Reasons for exclusion were: absence of invasive cer-
vical cancer (n = 1), sample in which confirmation of
cervical origin was not possible (n = 1), CIN I (n = 1), car-
cinosarcoma (n = 1), endometrial adenocarcinoma (n = 2),
cervicitis (n = 1), carcinoma in situ (n = 11) and sample
with normal endocervix and lack of ectocervix (n = 1).
Therefore, the study analyzed specimens from 175 pa-
tients, between 21 and 86 years of age. The histopatho-
logical confirmation was made by the local Pathology
laboratories. Stage of the disease was coded according to
the International Federation of Gynecology and Obstetrics
(FIGO) criteria [18]. All clinical and laboratorial data from
the patients were obtained from hospital charts.
The study and the written informed consent signed by
all patients or their legal representative were approved by
the Research Ethical Committees of Hospital das Clínicas-
Faculdade de Medicina da Universidade de São Paulo,
Instituto do Câncer do Estado de São Paulo (CAPPesq n°
0451/09) and Hospital de Câncer de Barretos – Fundação
Pio XII (protocol n°405/2010).
At ICESP, fresh tumor tissue was collected and immedi-
ately introduced into a tube containing Specimen Trans-
port Medium – STM (Qiagen, Gaithersburg, USA) and
transported to the Virology Laboratory of the Instituto de
Medicina Tropical – Universidade de São Paulo (IMT-
USP), where they were stored at −20°C. Tumor tissues col-
lected at HC-Barretos were immediately introduced into a
cryopreservation tube and sent to the hospital Tumor
Bank, where they were stored in liquid nitrogen, until
DNA extraction. After DNA extraction, samples were sent
to the Virology Laboratory of IMT-USP where all molecu-
lar tests were carried out.
DNA extraction
Tumor tissue DNA was extracted using QIAamp DNA
Mini Kit (Qiagen, Gaithersburg, USA) or NucleoSpin Tis-
sue kit (Macherey-Nagel GmbH&Co, Germany), according
to manufacturer’s instructions.
HPV DNA testing
DNA extracted from the 175 samples were submitted to
Linear Array HPV Genotyping Test (LA, Roche Molecu-
lar Diagnostics, Pleasanton, USA) for HPV detection
and genotyping. This commercial available assay is able
to detect 37 HPV types (HPV-6, 11, 16, 18, 26, 31, 33,
35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62,
64, 66, 67, 68, 69, 70, 71, 72, 73 (MM9), 81, 82 (MM4),
83 (MM7), 84 (MM8), IS39 and CP6108).
Statistical analyses
Statistical analyses were performed with EpiInfo6 software
(www.cdc.gov/epiinfo). ANOVA, Yates corrected chi
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square test or Fisher exact test, as appropriate, assuming
two-sided tests and a level of significance of 0.05.
Results
HPV DNA tests were conducted in tumor samples from
175 women with a histopathological diagnosis of inva-
sive cervical cancer. Three samples from ICESP were
considered inadequate due to the lack of β-globin and
HPV positive results and were further excluded from the
analysis.
Eighty (46.5%) patients were recruited at ICESP and 92
(53.5%) at HC-Barretos. Patient’s age ranged from 21 to 86
with a mean of 51.9 years (95% CI 49.7-54.1). Patients from
ICESP (mean 51.1 years, SD = 14.7 and 95% CI 47.8 – 54.4)
had similar mean age of the HC-Barretos’ patients (mean
52.6 years, SD = 15.0 and 95% CI 49.5 – 55.7) (p = 0.85).
Five patients from ICESP (6.2%) were less than 30 years
old. After histological assessment, 144 (83.7%) tumors were
classified as squamous cell carcinoma (SCC) and 28
(16.3%) as adenocarcinoma (ADC). The two hospitals had
similar frequencies of ADC (ICESP 16.2% versus HC-
Barretos 16.3%) (p = 0.99). Women with ADC had a similar
age of women with SCC (p = 0.91) (Table 1). Disease sta-
ging was defined according to FIGO. Most patients were
classified as stage II (44.8%), followed by stage I (24.4%),
stage III (18.0%), stage IV (11.0%) and for 1.8% stage was
unknown.
HPV detection and type-specific distribution
Among the 172 samples that showed a valid result on
Linear Array HPV Genotyping Test (LA), 170 (98.8%)
were HPV positive. One HPV negative sample was from
ICESP and the other one from HC-Barretos. Further in-
vestigation with additional amplification methods veri-
fied the presence of HPV DNA in those as well (data
not shown). Most infections were identified as single in-
fections (75.3%).
The frequency of HPV types is illustrated in Figure 1.
The five most frequent types were: HPV16 (77.6%), HPV18
(12.3%), HPV31 (8.8%), HPV33 (7.1%) and HPV35 (5.9%)
(Table 2). HPV-16 and/or HPV18 were detected in 90.0%
of the samples. HPV16 was the most frequent in single in-
fections (77.3%), followed by HPV18 (7.8%), HPV33 (7.0%),
HPV31 (3.9%), HPV35 (1.6%) and HPV45, 58 and 59
(0.8%, each). All other HPV types were detected only in
multiple infections. One sample from an HIV-infected pa-
tient was positive only for low-risk HPVs (HPV11 and
HPV62), all others were positive for at least one high-risk
HPV type. In both hospitals, HPV16 was the most fre-
quent, followed by HPV18 and HPV31 at ICESP and
HPV33 at HC-Barretos. At ICESP, the six most prevalent
HPV types were HPV16, HPV18, HPV31, HPV45, HPV35
and HPV33 (Table 2). As single infection, HPV16 was the
most prevalent (62.5%) followed by HPV18 (12.5%),
HPV31 and 33 (8.9%, each) and HPV35, 45, 58 and 59
(1.8%, each). At HC-Barretos, the most frequent HPV
types were HPV16, HPV18, HPV33, HPV31 and HPV35
(Table 2). HPV16 and HPV18 were present in 90.1% and
8.8% of the samples, respectively. HPV16 was the most fre-
quent also as single infection (88.9%), followed by HPV33
(5.6%), HPV18 (4.2%) and HPV35 (1.4%). No HPV31 posi-
tive sample was observed as single infection nor any
HPV45 positive case was identified at this site. HPV16 was
significantly more frequent at HC-Barretos than ICESP,
considering only single infections (p < 0.001) and also con-
sidering multiple infections (p < 0.001) and HPV45 was sig-
nificantly more frequent at ICESP than HC-Barretos’
samples (p = 0.02). HPV59 was present in only two adeno-
carcinoma samples (one as single infection and the other
in addition to HPV16).
The mean age at diagnosis of invasive cervical cancer
of patients infected only by HPV33 are higher than the
overall study population and that from patients infected
only by HPV16 (Figure 2).
Differences in the relative contributions of HPV types
by histological diagnosis were identified. ADC was cor-
related to HPV59 (p = 0.04) in the study population, but
when the analysis was made for each hospital separately
no correlation between HPV type and histological diag-
nosis was observed (Table 3).
Discussion
The present study evaluated geographic differences in HPV
genotypes among Brazilian women with invasive cervical
cancer recruited at two cancer reference hospitals located
at the same region of the country. Some differences be-
tween the results obtained in the two hospitals were ob-
served and could be attributable to the fact that these
hospitals attend populations with different origins and char-
acteristics, as patterns of sexual behavior (for example the
number of sexual partners and age of first intercourse).
Previous studies that evaluated ICC cases from Brazilian
women were conducted in all five regions of the country:
Eluf-Neto and colleagues (1994) evaluated 199 ICC cases
from São Paulo city (Southeast region) [13], Noronha
and colleagues (1999) analyzed 155 cases from Belém
(Northern region) [14], Rabelo-Santos and colleagues
(2003) conducted a study in Goiânia (Central region) and
analyzed paraffin-embedded tissues from 56 women [19]
Table 1 Mean age of the patients by histological
diagnosis
Mean age (SD)
Total (n = 172) ICESP (n = 80) HC-Barretos (n = 92)
ADC (n = 28) 46.6 (14.8) 46.1 (13.2) 47.1 (16.0)
SCC (n = 144) 53.0 (14.7) 52.1 (14.8) 53.7 (14.6)
ADC, adenocarcinoma; SCC, squamous cell carcinoma; SD, standard deviation.
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and Fernandes and colleagues (2010) carried a study in
Natal city (Northeast region) with 88 archival paraffin-
embedded tissues from women with ICC [16]. ICC samples
(n = 46) from Southern region (Porto Alegre city) of the
country were also evaluated in an international study
conducted by Bosch and colleagues (1995) [20].
In our study, 98.8% of the samples were HPV positive,
corroborating literature data stating that HPV infection is
a necessary cause of ICC [8]. Although sensitivity is the
most important factor governing HPV detection on ICC
due to the usual very low viral load in these cases, other
technical caveats may contribute to false negative results,
like HPV DNA variability on primers and probe binding
sites and partial deletions of HPV genes integrated into
cellular genome, among other factors.
The higher HPV prevalence obtained in our study in
comparison to others Brazilian studies that obtained rates
of 70.3% to 92% [13,14,16,19] and even among studies
conducted in different world regions, ranging from 73.1%
to 93% [11,20-22], could be explained by the use, in the
current study, exclusively of fresh tissue. Several studies
used paraffin-embedded specimens that can lead to a
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Figure 1 HPV genotypes frequencies in invasive cervical cancer that were positive for HPV DNA.
Table 2 HPV genotypes in invasive cervical cancer cases that were positive for HPV DNA
HPV type Total (n = 170)* 95% CI ICESP (n = 79)* 95% CI HC-Barretos (n = 91)* 95% CI
Single infection 128 (75.3%) 68.1-81.6 56 (70.9%) 59.6-80.6 72 (79.1%) 69.3-86.9
Multiple infection 42 (24.7%) 18.4-31.9 23 (29.1%) 19.4-40.4 19 (20.9%) 13.1-30.7
11 1 (0.6%) 0.01-3.2 1 (1.3%) 0.03-6.8 – –
16 132 (77.6%) 70.3-83.7 50 (63.3%) 51.7-73.9 82 (90.1%) 82.0-95.4
18 21 (12.3%) 7.8-18.3 13 (16.5%) 9.1-26.5 8 (8.8%) 3.9-16.6
31 15 (8.8%) 5.0-14.1 11 (13.9%) 7.2-23.5 4 (4.4%) 1.2-10.9
33 12 (7.1%) 3.7-12.0 6 (7.6%) 2.8-15.8 6 (6.6%) 2.5-13.8
35 10 (5.9%) 2.9-10.5 7 (8.9%) 3.6-17.4 4 (4.4%) 1.2-10.9
39 1 (0.6%) 0.01-3.2 1 (1.3%) 0.03-6.8 – –
45 9 (5.3%) 2.4-9.8 9 (11.4%) 5.3-20.5 – –
52 2 (1.2%) 0.1-4.2 – – 2 (2.2%) 0.3-7.7
53 1 (0.6%) 0.01-3.2 1 (1.3%) 0.03-6.8 – –
56 1 (0.6%) 0.01-3.2 1 (1.3%) 0.03-6.8 – –
58 3 (1.8%) 0.4-5.1 3 (3.8%) 0.8-10.7 – –
59 2 (1.2%) 0.1-4.2 1 (1.3%) 0.03-6.8 1 (1.1%) 0.03-6.0
62 2 (1.2%) 0.1-4.2 2 (2.5%) 0.3-8.8 – –
72 1 (0.6%) 0.01-3.2 – – 1 (1.1%) 0.03-6.0
73 3 (1.8%) 0.4-5.1 1 (1.3%) 0.03-6.8 2 (2.2%) 0.3-7.7
84 1 (0.6%) 0.01-3.2 – – 1 (1.1%) 0.03-6.0
* Frequency values are above 100% because multiple infections are counted more than once.
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lower HPV positivity rate because the fixation process de-
grades DNA [23,24]. Moreover, Linear Array is one of the
most sensitive HPV detection methods available.
In the present study the observed rate of single infections
(75.3%) is lower than reported by others [12,16,20,22]. A
meta-analysis that included 30,848 cases of ICC worldwide
showed that the proportion of HPV multiple infections in-
creased in the last years from 4% to 15% [12], probably
reflecting the use of commercial tests more prone to detect
multiple infections in recent studies. The high rate of mul-
tiple infections reported in the current investigation could
be due to the fact that we did not use an automated system
51.9
50.9
48.1
52.8
63.1
Figure 2 Mean age (95% CI) at diagnosis of invasive cervical cancer by HPV types. SI, single infections; HPV, human papillomavirus.
Table 3 HPV genotypes in invasive cervical cancer cases by histological diagnosis
Total ICESP HC-Barretos
HPV Type ADC (n = 27)* SCC (n = 143)* p value ADC (n = 12)* SCC (n = 67)* p value ADC (n = 15)* SCC (n = 76)* p value
11 – 1 (0.7%) >0.99 – 1 (1.5%) >0.99 – –
16 21 (65.5%) 111 (76.7%) 0.81 7 (58.3%) 43 (64.2%) 0.95 14 (93.3%) 68 (89.5%) >0.99
18 6 (20.7%) 15 (7.5%) 0.18 4 (33.3%) 9 (13.4%) 0.21 2 (13.3%) 6 (7.9%) 0.78
31 1 (3.4%) 14 (9.6%) 0.55 1 (8.3%) 10 (14.9%) 0.94 – 4 (5.3%) 0.96
33 – 12 (8.2%) 0.23 – 6 (8.9%) >0.99 – 6 (7.9%) 0.66
35 1 (3.4%) 9 (6.8%) >0.99 1 (8.3%) 6 (9.0%) >0.99 – 4 (5.3%) 0.96
39 – 1 (0.7%) >0.99 – 1 (1.5%) >0.99 – –
45 2 (17.2%) 7 (3.4%) 0.87 2 (16.7%) 7 (10.4%) 0.82 – –
52 – 2 (2.0%) >0.99 – – – – 2 (2.6%) >0.99
53 – 1 (0.7%) >0.99 – 1 (1.5%) >0.99 – –
56 – 1 (1.4%) >0.99 – 1 (1.5%) >0.99 – –
58 – 3 (2.0%) >0.99 – 3 (4.5%) >0.99 – –
59 2 (6.9%) – 0.04 1 (8.3%) – 0.30 1 (6.7%) – 0.33
62 – 2 (1.4%) >0.99 – 2 (3.0%) >0.99 – –
72 – 1 (0.7%) >0.99 – – – 1 (1.3%) >0.99
73 – 3 (2.0%) >0.99 – 1 (1.5%) >0.99 – 2 (2.6%) >0.99
84 – 1 (0.7%) >0.99 – – – 1 (1.3%) >0.99
* Frequency values are above 100% because multiple infections are counted more than once.
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in the hybridization step of Linear Array HPV Genotyping
Test, what may have allowed some degree of cross-
hybridization [25].
Our study confirms the universal contribution of the
eight most common HPV types (HPV16, 18, 31, 33, 35,
45, 52 and 58) in ICC samples. Studies conducted in Brazil
show that HPV16 is the most common type followed by
HPV18 [13,14,16,20], with the exception of the Central re-
gion where the second most prevalent type is HPV33 [19].
Another difference in the HPV type prevalence among the
different regions of Brazil is verified for HPV58, which is
the third most frequent HPV type in the Northeast region
[16] but shows a minor contribution in the other country
regions. However, comparison of data from different stud-
ies shall be taken with caution since there are substantial
methodological variations that may have influenced on the
overall HPV positivity, as paraffin-embedded versus fresh-
frozen tumors, and on the individual rate of HPV types,
obviously driven by the inclusion of type-specific detection
probes on the post-PCR hybridization steps. The depend-
ence of HPV detection rate on the methodology adopted
has been extensively analyzed on the meta-analysis
performed by Li et al. [12].
Our data shows that patients from both hospitals had
similar mean age, around 50 years old that is in agree-
ment with an international study that evaluated 10,575
ICC cases and reported a mean age of 51.4 years [11].
Brazilian studies conducted in different regions of the
country reported a similar mean age, with the exception
of Northeast region where patients were younger: South-
east region (52.1 years) [13], Northern region (51.5 years)
[14], Central region (49.1 years) [19] and Northeast re-
gion (47.3 years) [16].
The majority of samples were histologically classified as
SCC cases, while ADC was found in 16.3% of cases, a ratio
similar to that described by other studies [11,12], but
higher to ADC relative frequencies observed in previous
Brazilian studies that observed 3.2% [14], 4.5% [13], 6.8%
[15] and 7.1% [19], suggesting that ADC ratio is increasing
over time. However, in our study population, women with
ADC were not younger than those with SCC, as observed
in a study conducted in Peru that reported an increase in
the burden of ADC, particularly among young women
[26]. This rise in ADCs could be a consequence of well-
known limitations of cytology-based screening of ADC
precursor lesions since they are frequently located in the
endocervical canal, making them less accessible than SCC
precursor lesions for cytological detection [27].
We did not observe the correlation of HPV18 and
HPV45 with ADC as reported by others [11-13,16]. Our
findings associate HPV59, which is related to HPV45
(both belong to the Papillomaviridae family alpha-7 spe-
cies) [4], to ADC. However, HPV16 was also very fre-
quent in ADC cases, especially those from HC-Barretos.
Li and colleagues (2011) reported that HPV16 contribu-
tion to ADC increased significantly after 2006 [12].
The current series confirms that the detection of exclu-
sive low-risk HPV type in ICC is a rare event (one sam-
ple). This case, occurring in an HIV-infected heavily
immunosuppressed patient, was described in more details
elsewhere and remains unclear if and how a low-risk HPV
type may induce ICC [28]. HPV16 and HPV18 were the
two most frequent HPV types observed in the present
study both in multiple and single infections, in agreement
to other Brazilian studies [13,14,16,20], but some differ-
ences were observed between the two hospitals: a higher
frequency of HPV16, no single infection by HPV31 and
no infection at all by HPV45 were observed within HC-
Barretos samples. These differences observed between
hospitals could be explained by the fact that patients from
ICESP included in the present study are from São Paulo
city, São Paulo coastal region and also from Northeast re-
gion of the country, while HC-Barretos patients are from
small countryside cities of the central and southeast region
of the country, where there is a lower circulation of people
from other regions/countries making the introduction and
establishment of new HPV types a rare event. Fourteen
different HPV types were observed in the samples from
ICESP whereas in the samples from HC-Barretos ten dif-
ferent HPV types were observed. If we compare genotype
distribution at ICESP (São Paulo city) in this casuistic
compared to that found in samples from 20 years ago [13]
it can be observed that HPV 16 and 18 are increasingly
frequent, being detected respectively in 53.8% and 8.6% of
the older cases and in 63.3% and 16.5% of the current
cases. Invasive cervical cancer cases related to HPV33,
irrespectively of histological diagnosis, were detected in
older women compared to the global study population
and to the HPV16 infected subjects.
The women infected by HPV18 and 45 in our study
had similar age at ICC diagnosis compared to the global
study population, in disagreement with the lower aver-
age age of women ascribed to these HPV types reported
in other studies [11,22]. This lower average age is attrib-
uted to the fact that these HPV types are more likely to
integrate into the host genome [29] reflecting a faster
tumorigenesis and more aggressive clinical courses.
These studies [11,22] also observed a lower average age
of ICC diagnosis for women infected by HPV16.
Conclusions
To our knowledge, this is one of the largest studies
employing fresh tumor tissue of invasive cervical cancer
cases made in Brazil. The present study confirms the
continuing major role of HPV16 and 18 in invasive cer-
vical cancer on recent cases in Brazil, especially at HC-
Barretos. Fortunately, available vaccines do include these
HPV genotypes, predicting a significant decrease in ICC
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future incidence over vaccinated women, as only 10.0%
of cases would not be target by the current vaccines.
Also, ICC screening by existing molecular assays would
not require the inclusion of additional HPV genotypes,
as they don’t seem to contribute significantly to ICC epi-
demiology in the Brazilian population.
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